Ankang Li

Ankang Li's Title

Ankang Li currently holds the position of Executive Director, Chief Strategy and Financial Officer. In this role, he is responsible for steering the strategic and financial direction of the company, leveraging his extensive background in both finance and biomedical sciences. His dual focus ensures that the company not only remains financially robust but also strategically aligned with its long-term goals.

Ankang Li's Education and Expertise

Ankang Li boasts an impressive educational background, holding a Ph.D. in Biomedical Sciences from Baylor College of Medicine, a Juris Doctor degree from the University of Chicago Law School, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. Additionally, he is a Chartered Financial Analyst (CFA), which underscores his expertise in financial analysis and investment management. This unique blend of biomedical and legal education, paired with financial acumen, sets him apart as a multidimensional leader capable of navigating complex business and scientific landscapes.

Ankang Li's Background

Ankang Li began his illustrious career as a postdoctoral biomedical researcher at the Salk Institute, where he honed his research skills in a cutting-edge scientific environment. His career trajectory then took a significant turn towards finance and business development, highlighting his versatility. He has served in various high-impact roles including as CFO of Terns Biopharmaceuticals and Executive Director of Healthcare Investment Banking at Goldman Sachs. His background includes overseeing business development and licensing transactions at Merck Asia Pacific Innovation Hub and advising clients on capital markets and M&A transactions at Davis Polk and Ropes & Gray.

Ankang Li's Achievements

Throughout his career, Ankang Li has achieved significant milestones. At Terns Biopharmaceuticals, he played a crucial role as CFO, helping to steer the company through financial challenges and growth opportunities. During his tenure at Goldman Sachs, he was instrumental in healthcare investment banking, providing valuable insights and strategic direction. His work at Merck Asia Pacific Innovation Hub involved overseeing critical business development and licensing transactions, demonstrating his strategic and operational prowess. Additionally, his advisory roles at Davis Polk and Ropes & Gray have equipped him with a deep understanding of capital markets and M&A transactions, further cementing his reputation as a seasoned financial and strategic expert.